title: Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.
abstract: The FEV1 and urinary leukotriene E4 (LTE4) concentrations were determined in six aspirin-sensitive and six non-aspirin-sensitive asthmatic subjects before and after inhalation challenge with lysine-aspirin or placebo solution. Lysine-aspirin produced a mean fall in FEV1 of 26.7 +/- 4.9% (mean +/- SEM) in subjects with aspirin sensitivity and of 8.5 +/- 6.5% (mean +/- SEM) in non-aspirin-sensitive asthmatic subjects. The mean baseline urinary LTE4 concentration of 83 pg/mg creatinine (geometric mean [GM], range 15 to 326 pg/mg creatinine) in aspirin-sensitive subjects was significantly higher than the 33.8 pg/mg creatinine (GM, range 10 to 111 pg/mg creatinine) in non-aspirin-sensitive subjects (p = 0.02). In aspirin-sensitive subjects, inhalation challenge with lysine-aspirin produced a significant increase in urinary LTE4 concentration to 240 pg/mg creatinine (GM, range 60 to 1,113 pg/mg creatine), which was not observed after placebo challenge. There was no significant change in urinary LTE4 concentration after inhalation challenge with either lysine-aspirin or placebo solution in non-aspirin-sensitive asthmatic subjects. Thus, sulfidopeptide leukotrienes are released after inhalation of lysine-aspirin in aspirin-sensitive asthmatic patients.
authors.affiliation: Swiss Institute for Asthma and Allergy Research, Davos.
authors.forename: P E
authors.initials: PE
authors.lastname: Christie
authors.forename: P
authors.initials: P
authors.lastname: Tagari
authors.forename: A W
authors.initials: AW
authors.lastname: Ford-Hutchinson
authors.forename: C
authors.initials: C
authors.lastname: Black
authors.forename: A
authors.initials: A
authors.lastname: Markendorf
authors.forename: M
authors.initials: M
authors.lastname: Schmitz-Schumann
authors.forename: T H
authors.initials: TH
authors.lastname: Lee
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D001249:Asthma / Q000503:physiopathology / Q000652:urine*; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D017999:Leukotriene E4; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D013189:SRS-A / Q000031:analogs & derivatives* / Q000652:urine
chemical_list: D013189:SRS-A; D017999:Leukotriene E4; D008239:Lysine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate